Abstract:Background: Cytoplasmic inclusions containing TAR DNA-binding protein 43 kDa (TDP-43) are recognized as a major pathological feature of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, but more recently have been associated with several neurodegenerative conditions. Cyclophilin A (PPIA), a foldase and molecular chaperone, interacts with TDP-43 and influences its aggregation and function. The interaction between PPIA and TDP-43 is facilitated by PPIA Lysacetylation, which is reduced in peripheral blood mononuclear cells (PBMCs) of ALS patients showing signs of TDP-43 proteinopathy. In this study, we investigated the effect of lysine deacetylation inhibition to uncover the underlying mechanisms of TDP-43 proteinopathy in relation to PPIA acetylation, and to identify new therapeutic avenues. Methods: Through a screening of histone deacetylase (HDAC) inhibitors in a cellular model of TDP-43 proteinopathy, we identified vorinostat/SAHA, capable of increasing PPIA acetylation, as the most effective in reversing TDP-43 mislocalization. We confirmed its effect in PBMCs from ALS patients. Next, we explored its impact on proteinopathy and PPIA acetylation in a severe and fast-progressing TDP-43 overexpressing mouse model (Thy1-hTDP-43), using several molecular biomarkers as outcome measures, including neurofilament light chain (NfL) in plasma. Results: Thy1-hTDP-43 mice treated with SAHA showed a delayed onset of TDP-43 pathology, associated with PPIA nucleus-cytoplasm redistribution, lower levels of neurodegeneration and neuroinflammation markers, and improved neuromuscular function markers. However, over time, the broad-spectrum inhibitor SAHA was unable to counteract the two-fold overexpression of TDP-43 and led to the accumulation of side effects. When combined with the heat shock protein (HSP) co-inducer arimoclomol, a mitigation of the neurodegeneration was sustained. Moreover, a synergistic effect was observed in periphery, greatly enhancing tubulin acetylation and reducing pTDP-43 accumulation in the sciatic nerve. This resulted in a more pronounced reduction of NfL in plasma and acetylcholine receptor (AChR) γ-subunit expression in gastrocnemius muscle, indicating reduced axonal transport impairment and muscle denervation. Conclusions: This study suggests that HDAC inhibition, by increasing acetylated PPIA, could be beneficial in restoring TDP-43 localization and function. The combination of lysine deacetylation inhibition and HSP induction shows a synergistic effect in vivo and has potential as a therapeutic approach for patients.

The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ

AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models

Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets

A Brain-Targeting Lipidated Peptide for Neutralizing RNA-mediated Toxicity in Polyglutamine Diseases

Alleviating Neurodegeneration in Drosophila Models of PolyQ Diseases

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

UBQLN2-HSP70 axis reduces poly-Gly-Ala aggregates and alleviates behavioral defects in the C9ORF72 animal model

Inhibition of Polyglutamine Misfolding with D-Enantiomeric Peptides Identified by Mirror Image Phage Display Selection

Multiparameter phenotypic screening for endogenous TFEB and TFE3 translocation identifies novel chemical series modulating lysosome function

Proximity proteomics of C9orf72 dipeptide repeat proteins identifies molecular chaperones as modifiers of poly-GA aggregation

The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias

Co-aggregation of polyglutamine (polyQ) proteins is mediated by polyQ-tract interactions and impairs cellular proteostasis

Lysine deacetylation inhibition reverses TDP-43 mislocalization and in combination with arimoclomol ameliorates neuromuscular pathology

Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

Ribosome inhibition by C9ORF72-ALS/FTD-associated poly-PR and poly-GR proteins revealed by cryo-EM

Reduced C9orf72 expression exacerbates polyGR toxicity in patient iPSC-derived motor neurons and a Type I protein arginine methyltransferase inhibitor reduces that toxicity

Spinal cord phosphoproteome of a SCA2/ALS13 mouse model reveals alteration of ATXN2-N-term SH3-actin interactome and of autophagy via WNK1-MYO6-OPTN-SQSTM1